Core Insights - The company, Nuo Cheng Jian Hua, reported a strong revenue growth of 59.8% year-on-year for the first three quarters of 2025, reaching 1.12 billion yuan, primarily driven by the sales of its core product, the BTK inhibitor, Obinutuzumab [1] - The company expects to achieve breakeven for the full year of 2025, two years ahead of its profitability target, thanks to effective cost management and a significant licensing deal with Zenas [1] - The loss for the first three quarters of 2025 narrowed significantly by 74.8% to 70 million yuan, attributed to rapid revenue growth and improved cost efficiency [1] Group 1 - The licensing agreement with Zenas, valued at over 2 billion USD, is expected to enhance the company's financial performance and strategic value [1] - Zenas is advancing global Phase III clinical trials for Obinutuzumab in multiple sclerosis patients, which will further validate the drug's potential in autoimmune diseases [2] - The collaboration with Zenas alleviates future overseas development costs and allows the company to leverage Zenas's expertise in the autoimmune field [2] Group 2 - Nuo Cheng Jian Hua is strengthening its leadership in hematologic oncology with key therapies including Obinutuzumab, Tanibrutinib, and Mesutoclax [3] - The approval of Obinutuzumab for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma is expected to benefit more lymphoma patients [3] - The company aims to accelerate its globalization process and plans to push five to six innovative drugs for approval, with three to four products targeting global markets [3]

Core Insights - The overall performance of the Sci-Tech Innovation Board (STAR Market) has shown a significant recovery, with a 75% year-on-year increase in net profit for the third quarter, indicating strong resilience and growth quality among "hard tech" companies [1][3]. Financial Performance - In the first three quarters of 2025, STAR Market companies achieved operating revenue of 1,105.01 billion yuan, a year-on-year increase of 7.9%, and net profit of 49.27 billion yuan, up 8.9% [2]. - Excluding four leading photovoltaic companies, the overall revenue and net profit growth rates for the STAR Market were 14.6% and 30.6%, respectively, indicating an amplified growth momentum [2]. Growth Characteristics - Over 70% of companies on the STAR Market reported revenue growth, and nearly 60% saw net profit increases, with 158 companies experiencing net profit growth exceeding 50% [3]. - The STAR 50 Index companies accounted for 46% of the board's revenue and 50% of net profit, while the STAR 100 Index companies demonstrated high growth elasticity, with revenue and net profit increasing by 12% and 134%, respectively [3]. R&D Investment - The total R&D investment of STAR Market companies reached 119.75 billion yuan, which is 2.4 times the net profit, with a median R&D intensity of 12.4%, leading A-shares in R&D efforts [3]. Sector Performance - The integrated circuit industry saw a 25% year-on-year revenue increase and a 67% net profit increase among 121 related companies, with major players like SMIC and Hua Hong maintaining high capacity utilization [5]. - The artificial intelligence (AI) sector emerged as a new growth pillar, with significant revenue increases in various segments, including a nearly 24-fold increase for Cambrian and a 55% increase for Haiguang Information [6]. - The biopharmaceutical sector reported an 11% revenue increase and a 48% net profit increase, driven by the approval of new drugs and accelerated commercialization [7]. Policy Impact - The ongoing "1+6" reform and the establishment of the Sci-Tech Growth Layer have provided targeted support for unprofitable tech companies, with 35 companies in this layer reporting a 39% revenue increase and a significant reduction in net losses [3].

本文字数：1300，阅读时长大约2.5分钟 作者 | 第一财经 黄思瑜 11月13日晚，随着中芯国际（688981.SH，00981.HK）、诺诚健华（688428.SH，09969.HK）2家多地上市的红筹公司完成三季报业绩披露，科创 板592家公司的三季度"成绩单"正式揭晓。 2025.11. 13 前三季度，科创板公司实现营业收入1.105万亿元，同比增长7.9%；实现净利润492.68亿元，同比增长8.9%；扣非后净利润319.74亿元，同比增长 5.5%。其中，第三季度单季净利润同比大幅增长75%。 其中，超七成公司实现营收增长，近六成公司净利润增长。158家公司净利润增幅超过50%，46家公司扭亏为盈。科创50指数成分公司营收和净利润占 板块整体比重，分别保持在46%和50%的高位。科创100指数成分公司营收和净利润同比分别增长12%和134%。 今年6月，科创板"1+6"改革启动，设立科创成长层，精准支持未盈利科技型企业发展。从三季度业绩表现看，35家公司前三季度营收同比增长39%， 净利润同比大幅减亏65%；在增收缩亏的同时，研发强度中位数高达44.3%。 第一财经持续追踪财经热点。若您掌握公 ...

Performance Highlights - Tencent Holdings (00700.HK) reported Q3 revenue of 192.87 billion yuan, a year-on-year increase of 15% and a quarter-on-quarter increase of 5%. Net profit reached 63.13 billion yuan, up 19% year-on-year and 13% quarter-on-quarter [2] - Semiconductor Manufacturing International Corporation (00981.HK) achieved Q3 sales revenue of 2.38 billion USD, a quarter-on-quarter increase of 7.8% and a year-on-year increase of 9.7%. Gross margin improved to 22.0%, up 1.6 percentage points quarter-on-quarter [3] - JD Group (09618.HK) reported Q3 total revenue of 299.06 billion yuan, a year-on-year increase of 14.85%, while net profit decreased by 55.03% to 5.28 billion yuan [4] - JD Logistics (02618.HK) recorded Q3 revenue of 55.08 billion yuan, a year-on-year increase of 24.1%, with operating profit rising by 125.3% to 1.24 billion yuan [5] - Bilibili (09626.HK) achieved Q3 net revenue of 7.69 billion yuan (1.08 billion USD), a year-on-year increase of 5%, and turned a profit with a net profit of 469 million yuan (65.9 million USD) [6] Company News - Heng Rui Medicine (01276.HK) received clinical trial approval for its drug, with similar products expected to generate global sales of approximately 11.04 billion USD in 2024 [7] - China Pacific Insurance (02601.HK) reported that for the first ten months, life insurance premium income reached 241.32 billion yuan, a year-on-year increase of 9.9% [8] - Zhong An Online (06060.HK) reported total original insurance premium income of approximately 29.82 billion yuan for the first ten months, a year-on-year increase of 5.18% [9] Buyback Activities - Yongsheng Services (01995.HK) plans to repurchase up to approximately 173 million shares, accounting for about 10% of the issued share capital [12] - Kintor Pharmaceutical (02171.HK) intends to repurchase up to approximately 25.46 million shares [13] - China Feihe (06186.HK) spent 87.86 million HKD to repurchase 20 million shares at prices ranging from 4.37 to 4.40 HKD [14]

11月13日晚，随着中芯国际（688981.SH，00981.HK）、诺诚健华（688428.SH，09969.HK）2家多地上 市的红筹公司完成三季报业绩披露，科创板592家公司的三季度"成绩单"正式揭晓。 前三季度，科创板公司实现营业收入1.105万亿元，同比增长7.9%；实现净利润492.68亿元，同比增长 8.9%；扣非后净利润319.74亿元，同比增长5.5%。其中，第三季度单季净利润同比大幅增长75%。 其中，超七成公司实现营收增长，近六成公司净利润增长。158家公司净利润增幅超过50%，46家公司 扭亏为盈。科创50指数成分公司营收和净利润占板块整体比重，分别保持在46%和50%的高位。科创 100指数成分公司营收和净利润同比分别增长12%和134%。 今年6月，科创板"1+6"改革启动，设立科创成长层，精准支持未盈利科技型企业发展。从三季度业绩表 现看，35家公司前三季度营收同比增长39%，净利润同比大幅减亏65%；在增收缩亏的同时，研发强度 中位数高达44.3%。 新能源行业"反内卷"持续推进。光伏领域，17家相关企业净亏损幅度收窄，环比缩亏28%。部分环节产 品均价有所回升，硅料龙头大全能 ...

Core Viewpoint - The announcement from Nocera Health indicates significant changes in the top ten circulating shareholders as of September 30, 2025, with new entrants and exits among major shareholders [1][2][3] Shareholder Changes - HKSCC NOMINEES LIMITED has entered as a new shareholder, holding 892 million shares, representing 50.55% of circulating shares [1][3] - Sunny View Holdings Limited and Renbin Zhao family have maintained their position with 145 million shares, accounting for 8.21% [1][3] - Sunland BioMed Ltd and Jisong Cui family also entered with 127 million shares, making up 7.2% [1][3] - King Bridge Investments Limited and its concerted actions hold 122 million shares, representing 6.92% [1][3] - Other new shareholders include Wan Jia You Xuan with 10 million shares (0.57%) and Ping An Medical Health Mixed A with 8.63 million shares (0.49%) [1][3] Shareholder Exits and Reductions - HKSCC NOMINEES LIMITED previously held 882 million shares (50.02%) before exiting [2][3] - King Bridge Investments Limited and its concerted actions reduced their holdings from 133 million shares (7.54%) [2][3] - The report notes a reduction in holdings for 富国精准医疗灵活配置混合A, decreasing by 3.39% to 12.15 million shares [2][3] - 汇添富创新医药混合A also saw a reduction of 9.78% to 6.86 million shares [2][3] Overall Shareholder Composition - The top ten circulating shareholders collectively hold 1.54 billion shares, accounting for 87.28% of circulating shares, which is a decrease of 6.9795 million shares from the previous report [3]

Core Insights - The overall net profit of the Sci-Tech Innovation Board companies saw a significant year-on-year increase of 75% in the third quarter, reflecting strong resilience and growth quality in the "hard technology" sector [2][3]. Financial Performance - For the first three quarters of 2025, the companies on the Sci-Tech Innovation Board achieved total operating revenue of 1,105.01 billion yuan, a year-on-year increase of 7.9%, and a net profit of 49.27 billion yuan, up 8.9% [2]. - Excluding four leading photovoltaic companies, the overall revenue and net profit of the board increased by 14.6% and 30.6% respectively, indicating an amplified growth momentum [2]. - Over 70% of companies reported revenue growth, and nearly 60% saw net profit increases, with 158 companies experiencing net profit growth exceeding 50% [2]. R&D Investment - The total R&D investment of the Sci-Tech Innovation Board reached 119.75 billion yuan, which is 2.4 times the net profit, with a median R&D intensity of 12.4%, leading all A-share sectors [3]. - 35 unprofitable companies in the newly established growth tier reported a revenue increase of 39% year-on-year, while their net profit losses decreased by 65% [3]. Industry Highlights - The integrated circuit industry, a core area for technological self-reliance, saw 121 related companies achieve a revenue increase of 25% and a net profit increase of 67% [5]. - The artificial intelligence sector emerged as a new growth pillar, with significant revenue increases reported by key players such as Cambrian and Haiguang [6]. - The biopharmaceutical sector experienced an 11% revenue increase and a 48% net profit increase, with nine new class 1 drugs approved for market [6]. Market Dynamics - The photovoltaic sector benefited from "anti-involution" policies, with 17 related companies significantly reducing their losses by 28% [7]. - The lithium battery industry saw a revenue increase of 7% year-on-year, with a net profit of 1.02 billion yuan, marking a return to profitability for 19 companies [7].

Monetary Policy and Financing - As of the end of October, the broad money supply (M2) reached 335.13 trillion yuan, showing a year-on-year growth of 8.2% [1] - The total social financing stock was 437.72 trillion yuan, with a year-on-year increase of 8.5% [2] - The net cash injection in the first ten months amounted to 728.4 billion yuan [1] Company Financial Performance - Tencent Holdings reported third-quarter revenue of 192.87 billion yuan, a 15% increase year-on-year, with net profit rising 19% to 63.13 billion yuan [3] - JD Group's third-quarter revenue was 299.1 billion yuan, reflecting a year-on-year growth of 14.9%, but net profit decreased to 5.3 billion yuan from 11.7 billion yuan in the previous year [4] - Semiconductor manufacturer SMIC achieved a net profit growth of 41.1% year-on-year for the first three quarters, with revenue of 49.51 billion yuan [5] Industry Trends - The memory chip industry is expected to see continued capital expenditure growth, although it may have limited impact on bit output growth in 2026 [6] - The launch of the first autumn holiday in China has led to a 7% increase in average ticket prices for popular domestic routes [6] Corporate Developments - Alibaba has secretly initiated the "Qianwen" project to develop a personal AI assistant, aiming to compete directly with ChatGPT [6] - Glencore and Hillhouse Capital plan to participate as cornerstone investors in the upcoming IPO of Chuangxin Industries in Hong Kong, indicating confidence in the aluminum sector [8] - Evergrande Group has been executed for a total of 3.19 billion yuan across multiple cases, highlighting ongoing financial distress [9] Stock Market Activity - The Shanghai Composite Index rose by 0.73%, reaching a ten-year high, with significant gains in the lithium battery sector and consumer goods [24]

Core Insights - The company expects to achieve its profitability target two years ahead of schedule, with a projected breakeven in 2025 [1][2] Financial Performance - In the first three quarters, the company's total revenue increased by 59.8% year-on-year, reaching 1.12 billion yuan, while the net loss narrowed by 74.78% to 72 million yuan [1] - Revenue from the core product, BTK inhibitor Oubatinib, reached 1.01 billion yuan in the first three quarters, surpassing the total revenue of the previous year [1] Strategic Partnerships - The company entered a licensing agreement with Prolium, which includes an upfront payment of 17.5 million USD and potential milestone payments totaling up to 503 million USD based on specific clinical and regulatory achievements [1] - A significant licensing agreement with Zenas regarding Oubatinib and other autoimmune pipeline products was established, with a total transaction value exceeding 2 billion USD, including an upfront payment of 100 million USD [2] Research and Development - Research and development expenses increased by 9.9% year-on-year, amounting to 680 million yuan for the first three quarters of 2025 [2] - The company aims to push five to six innovative drugs for approval and globalize three to four products, while developing five to ten differentiated clinical candidates [2] Cash Position - As of September 30, 2025, the company held approximately 7.76 billion yuan in cash and cash equivalents [2]

Core Insights - Nuo Cheng Jian Hua reported a significant revenue increase of 59.8% year-on-year for the first three quarters of 2025, reaching 1.12 billion yuan, primarily driven by the sales growth of its core product, the BTK inhibitor Aobutini (Yinokai®) [2][5] - The company expects to achieve breakeven for the entire year of 2025, two years ahead of its profitability target, supported by strong revenue growth and improved cost efficiency [2][5] Financial Performance - Aobutini's revenue for the first three quarters increased by 45.8% year-on-year, totaling 1.01 billion yuan, surpassing the total revenue for the previous year [2] - The company's loss narrowed significantly by 74.8%, down to 70 million yuan, due to rapid revenue growth and enhanced cost management [2] Globalization Strategy - Nuo Cheng Jian Hua is accelerating its globalization efforts, having completed two major licensing agreements this year, including a significant deal with Zenas for Aobutini and other autoimmune pipeline products [3][4] - The agreement with Zenas includes an upfront payment of 100 million USD and potential milestone payments, with the total deal value exceeding 2 billion USD [3] Product Pipeline and Market Position - The company is strengthening its leadership in the hematological oncology market with Aobutini, Tanshizhu Single Antibody (Mingnuokai®), and Mesutoclax, covering multiple indications [6] - Aobutini has been approved for first-line treatment of CLL/SLL, enhancing its market position [6][7] - Tanshizhu Single Antibody has been fully commercialized in China, providing a new treatment option for R/R DLBCL patients [8] Clinical Development - Mesutoclax is undergoing multiple clinical trials, showing significant potential in treating CLL/SLL and AML, with promising efficacy and safety data [9][10] - The company is advancing several Phase III clinical trials for autoimmune diseases, including Aobutini for primary progressive multiple sclerosis (PPMS) and immune thrombocytopenic purpura (ITP) [12][14] Innovation and R&D - Nuo Cheng Jian Hua is committed to innovation, with a 9.9% increase in R&D expenses, reaching 680 million yuan in the first three quarters of 2025 [19] - The company plans to submit 5 to 7 clinical trial applications for new drug candidates in 2026, focusing on oncology and autoimmune diseases [20]